2026 Psychiatry Practice Market Update

Olympic M&A · 2026 Market Update

2026 Psychiatry Practice Market Update

The First Real Consolidation Wave in Psychiatry Is Here.

What It Means for Your Practice.

The most underbuilt corner of American medicine is also the most heavily demanded. That is the opportunity.

If you own a psychiatry practice — outpatient psychiatry, child and adolescent psychiatry, geriatric psychiatry, TMS-focused psychiatry, or a multi-provider psychiatry group — you have built something that has quietly become one of the most sought-after assets in healthcare M&A.

If you own a psychiatry practice, you have probably asked at least one of these questions:

Is consolidation in psychiatry real, or is the noise overstated?
How much is my psychiatry practice actually worth in today's market?
Are private equity firms genuinely interested in a psychiatry practice my size?
What should I be doing right now to protect and maximize my options?
If I do not want to sell yet, what do I lose by waiting?

The most underbuilt corner of American medicine is also the most heavily demanded. That is the opportunity.

If you are thinking about selling your psychiatry practice — or simply want to understand what it is worth before you ever have to make a decision — you are in the right place.

For most of the last decade psychiatry has been talked about as the "next" healthcare consolidation wave. In 2025 it stopped being next. It became one of the most active corners of healthcare M&A in the country, with PE-backed psychiatry platforms acquiring independent psychiatry practices at a pace the specialty has never seen before. Institutional capital is no longer testing the category. It is buying it.

The window is open. Based on what has happened in every comparable healthcare specialty before this one — it will not stay open forever.

The Numbers That Define the Psychiatry Practice Market Right Now

~30,000

Practicing psychiatrists in the United States serving a population of more than 330 million

American Medical Association — Physician Specialty Data Report

~1,400

New psychiatry residency graduates entering U.S. practice annually. The math does not close.

AAMC Physician Workforce Reports

~60%

Of practicing psychiatrists are aged 55 or older — the retirement cliff is not theoretical

AAMC State Physician Workforce Data Report

The psychiatry practice market is not a niche. It is a structurally undersupplied, fast-growing specialty that institutional capital is actively trying to consolidate for the first time in the specialty's history.

Why This Moment in Psychiatry Is Different

To understand why buyers are interested in your psychiatry practice, you need to understand what is happening to the system around it.

Psychiatry sits in a structural supply-demand mismatch unlike any other medical specialty. Demand for psychiatric care has accelerated meaningfully and continues to climb. Supply — credentialed psychiatrists — has not kept pace and will not for at least a decade.

1 in 5

U.S. adults experienced a diagnosable psychiatric condition in the past year. Less than half received any psychiatric care.

National Institute of Mental Health (NIMH)

1 in 3

Americans live in a designated Mental Health Professional Shortage Area — a documented unmet need buyers underwrite directly into valuations.

HRSA, Health Workforce Shortage Designations

76 days

Average wait time for a new patient to see a psychiatrist in major U.S. metro areas — the longest of any major medical specialty.

Merritt Hawkins Survey of Physician Appointment Wait Times

$300–$500+

Average reimbursement per outpatient psychiatry medication management visit in commercial-payer-heavy practices.

AMA CPT Code references & commercial payer fee schedules

You provide a service that is structurally undersupplied, structurally in demand, and structurally protected from the reimbursement volatility that has hurt other specialties. Mental health parity rules — most recently tightened by the final rule under the Mental Health Parity and Addiction Equity Act — have meaningfully improved psychiatry reimbursement compared to a decade ago. That changes the economics of every psychiatry practice in the country.

That is the system buyers see. And that is why they are calling psychiatry practice owners.

The Signal the Psychiatry Practice Market Is Already Sending

You do not have to take anyone's word for what is happening in psychiatry. You can look at where institutional capital is already deployed — specifically in psychiatry.

The Most Active Specialty in Healthcare M&A Since 2022

PE-backed psychiatry-focused platforms — including LifeStance Health, Mindpath Health, Talkiatry, Octave, Brightside, Headway, and ARC Health Partners — are actively acquiring independent psychiatry practices nationally. Each of these platforms is buying because the underlying psychiatry economics work, and each is competing for a finite pool of high-quality independent psychiatry practices.

According to public deal-tracking sources and industry reporting from PitchBook's healthcare reports, psychiatry-focused acquisitions have ranked among the most active healthcare specialty roll-ups in the United States for three consecutive years.

What Buyers Have Already Demonstrated

LifeStance Health went public in 2021 at a multi-billion-dollar valuation built specifically on consolidating outpatient psychiatry practices.
Mindpath Health has completed dozens of independent psychiatry acquisitions over the past 36 months at psychiatry practice multiples that materially exceed historical valuations.
Talkiatry and Headway have raised meaningful institutional capital specifically to acquire and integrate psychiatry providers and practices at national scale.

When the most sophisticated capital in the country pays a premium for a psychiatry platform, that is not a trend. That is a verdict.

What This Means for Your Practice

The independent psychiatry practice market remains overwhelmingly fragmented. Most psychiatry practice owners in the United States today are still independent. Buyers competing for a small pool of high-quality, available, well-prepared independent psychiatry practices creates a dynamic that favors prepared psychiatrist sellers.

Dermatology consolidated. Dental consolidated. Ophthalmology consolidated. Radiology consolidated. Each of those specialties rewarded early platform buyers at premium multiples and punished late arrivals at lower ones.

Psychiatry is in the early-to-middle innings of that same cycle. The psychiatry practice owners who prepare now will define their own terms. The ones who wait will react to terms set by others.

What Makes Your Psychiatry Practice Attractive to Buyers

When a sophisticated buyer evaluates your psychiatry practice, they are not looking at what you see every day. They are looking at the structural fundamentals that make psychiatry one of the most attractive medical specialties in the country.

~85%+

Outpatient psychiatry visit completion rate at well-run practices, materially higher than many medical specialty comparables

Industry benchmark

70–95%

Telehealth-eligible portion of outpatient psychiatry — the highest of any non-radiology medical specialty

Industry benchmark

Recurring

Patient relationships through medication management — predictable follow-up volume per patient per year

Industry benchmark

These structural advantages describe your psychiatry practice. They also describe exactly what institutional buyers are looking for: durable cash flow, reimbursement protection, telehealth scalability, and clinical demand that does not require marketing spend.

Here is the complete picture of what buyers see when they evaluate a well-run psychiatry practice:

Predictable, recurring patient demand — driven by a structural national psychiatrist shortage that pre-dates COVID and will outlast 2030
Strong commercial-payer mix in many psychiatry practices, with parity-protected psychiatric reimbursement
High telehealth scalability — most outpatient psychiatry care can be delivered virtually, expanding geographic reach without proportional cost
Recurring revenue patterns through medication management and TMS treatment courses
Limited capex requirements compared to procedural specialties — psychiatry is largely a knowledge-and-time business
High-margin ancillaries — TMS, Spravato (esketamine), psychiatric testing — each with its own buyer thesis
Defensible workflows that can be standardized across multiple psychiatrists and locations

When a buyer evaluates your psychiatry practice they are not just buying revenue. They are buying a model. They are buying access to a clinically scarce specialty. They are buying predictable margin in a healthcare market defined by reimbursement volatility.

Who Is Actually Buying Psychiatry Practices Right Now

There is no single buyer profile in psychiatry M&A. Understanding who is approaching your market — and what each buyer type specifically wants — is one of the most important things you can know before any conversation begins.

PE-Backed Psychiatry Platforms

The most active buyer category in psychiatry M&A. Platforms including LifeStance, Mindpath Health, Talkiatry, Octave, Brightside, Headway, and ARC Health are acquiring independent practices to scale nationally. They move quickly, do their homework before they call, and compete for a finite pool — typically paying the highest psychiatry multiples for practices with multiple psychiatrists, strong commercial payer mix, and demonstrable telepsychiatry capability.

Strategic Payer Buyers

Several large insurers and integrated delivery systems have built or acquired psychiatry capability to manage utilization, capture reimbursement spread, and meet parity-driven psychiatric service expectations. They tend to value scale and geographic coverage. Not always the fastest movers — but often pay competitively for the right asset.

Physician-Owned Psychiatry Platforms

Psychiatrist-led groups expanding through acquisition. These buyers often offer attractive cultural fit for psychiatrist-sellers who want their practice to remain physician-led after closing. Multiples are typically slightly below PE psychiatry platforms but the post-close experience can be meaningfully better for the seller and the patients.

Family Offices & Long-Term Hold Capital

A smaller but growing category in psychiatry M&A. Family offices acquiring psychiatry practices as long-duration healthcare assets with predictable cash flow. Less common at the smaller end of the market — more relevant for $2M+ EBITDA psychiatry practices.

Hospital Systems & Academic Psychiatry Departments

Less competitive on price but relevant for psychiatrists who prioritize academic affiliation, integration with broader medical care, or specific community-mission alignment.

The right buyer for your psychiatry practice is not necessarily the one with the highest first offer. It is the buyer whose model, values, and long-term vision align most closely with what you built.

The best way to sell a psychiatry practice is to run a process that brings multiple qualified psychiatry buyers to the table — so you are choosing rather than accepting.

How Your Practice Was Valued Then — And How It Is Valued Now

If you have ever thought about what your psychiatry practice might be worth, you probably had a number in your head. That number was almost certainly built on how psychiatry practices were valued five or ten years ago — small EBITDA multiples, heavily discounted owner dependency, a buyer universe limited to local hospital systems or competing psychiatry practices.

That model has changed.

Historically, an independent psychiatry practice would have been valued at modest multiples on the psychiatrist's income, with the most likely buyer being a hospital system or a competing local psychiatry practice. The valuation framework was conservative because the buyer universe was narrow and the strategic case was thin.

Today, sophisticated PE-backed and payer-led psychiatry platform buyers evaluate your practice on structural fundamentals — payer mix, EBITDA quality, psychiatrist productivity, telepsychiatry penetration, reimbursement durability, and platform scalability. The buyer universe has broadened materially. The competitive dynamic between psychiatry buyers has driven multiples up across the specialty.

That shift changes everything about how your psychiatry practice is valued. The number in your head may be significantly lower than what a competitive psychiatry process would actually produce in 2026. That is not an accident — it is the result of never having seen your practice through a sophisticated buyer's eyes.

That is exactly what this report is designed to change.

What Drives the Value of Your Psychiatry Practice in 2026

Understanding what drives psychiatry practice valuation today is one of the most important things you can do before any buyer conversation begins. Two psychiatry practices with similar revenue can look very different through a buyer's eyes. The difference is rarely visible on the surface — and that gap is often worth hundreds of thousands of dollars in outcome.

Your psychiatry practice commands a stronger valuation when it demonstrates:

Multiple psychiatrists and reduced founder dependency — practices that can operate without the owner-psychiatrist carrying every patient relationship
Clean, accrual-based financials with documented EBITDA and clearly explained add-backs
Strong commercial-payer mix — meaningful commercial revenue (vs. heavy Medicaid or Medicare concentration) typically commands higher multiples
Operational systems beyond the founding psychiatrist — documented workflows, EMR/PM infrastructure, credentialing, billing, and compliance signaling scalability
Telepsychiatry capability and patient volume — buyers reward practices that have already proven they can deliver virtual care effectively
High-margin psychiatry ancillaries — TMS, Spravato, and psychiatric testing each raise the multiple if managed properly
Compliance maturity — particularly around controlled substances, telepsychiatry regulations, and HIPAA

Psychiatry Practice Size and Multiple Ranges

Psychiatry practice size matters significantly in valuations.

Solo psychiatrist practices

Clean fundamentals

5x to 6.6x on normalized EBITDA, depending on payer mix, telepsychiatry penetration, and psychiatry ancillary depth

Multi-psychiatrist practices

3–10 psychiatrists, operational depth

5.5x to 7x with stronger candidates moving above that range in a competitive process

Platform-scale practices

$2M+ EBITDA, multi-location, multi-state

7x to 10x+ in a competitive process with PE-backed psychiatry buyers

Psychiatry practices with significant TMS or Spravato service lines often command meaningfully higher multiples than pure outpatient medication-management practices because the buyer's growth thesis is more visible.

A $200,000 improvement in documented EBITDA × 6x multiple = $1.2 million in additional enterprise value.

Small improvements in your fundamentals can create substantial increases in value. Preparation directly impacts your outcome.

What You Are Actually Worried About

You are probably not lying awake thinking about EBITDA multiples.

You are thinking about your patients. Your prescribing autonomy. Your team. The 14-year relationships you have with patients managing complex psychiatric conditions, and whether those will survive contact with a private equity buyer.

Those concerns are valid. And they are the questions most M&A advisors are not equipped to answer — because they have never been inside an outpatient psychiatry practice.

If I sell to a psychiatry platform, will they push me to see more patients per hour or shorten medication management visits?
Will my prescribing autonomy be respected, particularly around controlled substances?
How will my staff be treated after the transaction?
Will corporate quotas reshape the psychiatry culture I built?
Will my patients feel like they were sold to a faceless platform?
Is this buyer experienced in psychiatry specifically — or learning on my practice?
What happens to my DEA registration, credentialing, and prescribing protocols post-close?

These are not questions most generalist investment bankers focus on. They are the questions you ask privately — and they deserve direct answers from someone who specializes in psychiatry M&A.

Not all capital behaves the same way.

The right partnership preserves your clinical autonomy, enhances your psychiatry infrastructure, and strengthens what you built. The wrong one can quietly dismantle it.

Experience in psychiatry specifically — not generic healthcare M&A — is the difference.

Where Do You Want to Take Your Psychiatry Practice?

Not every psychiatrist reading this is thinking about selling. And that is exactly the point.

You may want to grow your practice and increase its value before ever going to market.
You may want to explore a partnership that lets you stay clinically active while gaining liquidity, infrastructure, and shared overhead.
You may want to plan a full transition on your terms — your timeline, your successor, your prescribing philosophy, your legacy.
You may simply want to understand what your practice is worth right now — with no obligation, no timeline, and no pressure.

Whatever your timeline, building a psychiatry practice exit strategy early gives you options that waiting will never give you. The psychiatrists who start this conversation before they need to are the ones who define their own terms.

Preparation doesn't mean you're selling.

It means you're in control.

Knowing what your practice is worth and what your options look like gives you leverage in any conversation — whether that conversation happens in 12 months or never.

Why 2026 Is a Defining Year for Psychiatry Practice Owners

Psychiatry has matured as an institutional investment category. Your specialty has proven itself — financially, clinically, and structurally. Patients value access. Reimbursement is parity-protected. Telepsychiatry is permanent. Investors value recurring psychiatric demand.

When institutional capital enters a medical specialty at scale for the first time, early consolidation phases historically create the strongest valuation environments. Not because buyers are generous — but because competition among buyers is highest and the market has not yet established a ceiling.

That is where psychiatry sits right now.

Three specific mistakes psychiatry practice owners make in this moment materially reduce their outcome. We cover all three in the webinar — along with exactly what to do instead.

01

Reacting to an inbound psychiatry offer instead of running a process. Single-buyer conversations almost always price below what a competitive psychiatry process would have produced.

02

Going to market before financial documentation, payer mix data, and psychiatrist productivity reporting are clean. Buyers price uncertainty as discount.

03

Underestimating the value of telepsychiatry penetration, psychiatry ancillaries, and reduced owner dependency. These are exactly the levers that move a multi-psychiatrist practice from a 5x outcome to a 7x outcome.

The best way to sell a psychiatry practice is not to wait until you are ready to sell. It is to prepare while you still have time to strengthen your position — so that when the right conversation happens, you walk into it with leverage.

The most sophisticated psychiatrists in your position are not rushing to sell.

They are quietly preparing.
Strengthening their fundamentals.
Reducing owner dependency.
Building telepsychiatry volume.
Cleaning up financials.
Understanding how buyers evaluate a practice like theirs.

That is exactly what this report is designed to change.

Your Next Step

The Private Psychiatry Practice Webinar

We host a private, psychiatrist-only webinar covering exactly what is in this report — and the specific steps you can take right now to protect your value and your options.

If you are asking how to sell a psychiatry practice — or simply how to understand what yours is worth — this session is built for you.

In this session you will leave knowing

Exactly what your psychiatry practice is worth in today's market — and what is driving or limiting that number
The three mistakes that cost psychiatrists millions — and how to avoid every one of them
What separates a high-value psychiatry practice from a low-value one in the eyes of a sophisticated buyer
How to strengthen your position before any buyer approaches you — whether you transact in 12 months, 36 months, or never

This session is limited to 10 psychiatrists so Tony can answer your specific questions directly. It is a real conversation — not a presentation. Tony reads every question submitted before the session.

Prefer a private conversation about your specific psychiatry practice first?

Or get a quick estimate of your practice value with the psychiatry practice valuation calculator.

Free Download

Send Me the Free Psychiatry Practice Report

Delivered to your inbox immediately. No webinar. No sales call. No obligation. Just the most important market intelligence available for psychiatry practice owners right now.

About Tony Siebel

Tony Siebel is the Founder and Managing Director of Olympic M&A — a specialized M&A advisory firm serving psychiatry practice owners in the lower middle market. Olympic M&A represents psychiatrist sellers, with deep experience advising owners of outpatient psychiatry practices, TMS-focused psychiatry practices, and multi-psychiatrist groups through complete sale processes.

Tony has advised on $70M+ in completed healthcare M&A transactions and was named a Top 50 M&A Advisor in 2025. Olympic M&A operates on a success-fee model — Tony only gets paid when a psychiatry practice deal closes — and offers pre-exit advisory services that help psychiatrists prepare for sale 12 to 24 months before they ever go to market.

Tony's perspective for psychiatry practice owners

They are quietly preparing.
Advisor on $70M+ in completed healthcare M&A transactions
Former MDVIP Director of Corporate Development — direct experience acquiring physician practices nationally
Recruited and evaluated more than 60 physicians nationwide
Owner-operator of a behavioral healthcare firm — first-hand operator perspective on clinical autonomy and partnership structure

Tony's expertise in the psychiatry and TMS industry is unparalleled. When it came to valuing our practice and identifying potential buyers, Tony's deep knowledge and connections in this specialized field were invaluable. He understood the unique dynamics of this market and knew exactly who the key players and potential psychiatry buyers were.

— Brian E., MD · Psychiatry Practice Owner

Tony has published 60+ articles on healthcare M&A, including specialized work on psychiatry practice valuation, psychiatry practice consolidation, and psychiatrist transition strategy.

Every conversation with Tony is built on a single principle:

Olympic M&A works for the psychiatrist seller, not the buyer.